Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Eletriptan
Drug ID BADD_D00755
Description Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.
Indications and Usage For the acute treatment of migraine with or without aura in adults.
Marketing Status approved; investigational
ATC Code N02CC06
DrugBank ID DB00216
KEGG ID D07887
MeSH ID C115647
PubChem ID 77993
TTD Drug ID D02DMQ
NDC Product Code Not Available
UNII 22QOO9B8KI
Synonyms eletriptan | (R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole | UK 166,044 | UK-166044 | UK 166044 | UK-166,044 | Relpax | UK-116044-04 | UK-116,044-04 | eletriptan hydrobromide | (R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole monohydrobromide | 3-(1-methyl-2-pyrrolidinylmethyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole hydrobromide
Chemical Information
Molecular Formula C22H26N2O2S
CAS Registry Number 143322-58-1
SMILES CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin hypertrophy23.01.04.002--Not Available
Sleep disorder19.02.04.0010.000795%Not Available
Somnolence17.02.04.006; 19.02.05.0030.002566%
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.002205%Not Available
Sputum increased22.02.03.007--Not Available
Stomatitis07.05.06.005--
Stress19.06.02.0040.001410%Not Available
Stupor19.02.05.004; 17.02.04.007--Not Available
Subarachnoid haemorrhage24.07.04.004; 17.08.01.010; 12.01.10.0110.000542%Not Available
Supraventricular tachycardia02.03.03.0120.001410%
Swollen tongue23.04.01.014; 07.14.02.003; 10.01.05.015--Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.000361%
Tachycardia02.03.02.0070.001699%Not Available
Tenosynovitis15.07.01.004--Not Available
Tension19.06.02.005--Not Available
Therapeutic response unexpected08.06.01.0010.001229%Not Available
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Thirst08.01.09.021; 14.03.02.007--Not Available
Throat tightness22.12.03.031; 19.01.02.0050.001084%Not Available
Thrombophlebitis24.01.02.001--Not Available
Thyroid adenoma16.37.01.001; 05.02.05.003--Not Available
Thyroid disorder05.02.01.0020.000361%Not Available
Thyroiditis05.02.04.001--Not Available
Tinnitus17.04.07.004; 04.04.01.0020.000795%
Tongue disorder07.14.01.002--Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.007--Not Available
Tooth disorder07.09.05.0010.001410%Not Available
Tremor17.01.06.0020.000723%
Trismus17.01.03.004; 15.05.04.0040.000361%
Urethral disorder20.07.01.002--Not Available
The 8th Page    First    Pre   8 9 10    Next   Last    Total 10 Pages